The chart below shows the treatments the researchers planned to study.
- Acalabrutinib and BSC BSC only
- 31 participants 31 participants
- 100 mg of acalabrutinib as capsules by mouth
- BSC as decided by the study doctors
- acalabrutinib twice a day for 10 days
- BSC as decided by the study doctors

What happened during this study? The participants were in the study for about 3 months. But, the entire study took 5 months to finish. The study started in June 2020 and ended in November 2020. The COVID-19 pandemic did not affect the way the study was done, the results of the study, or the conclusions of the researchers.